Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.

ABSTRACT:

Background

The O ⁶ -methylguanine methyltransferase (MGMT) gene is frequently unmethylated in patients with glioblastoma (GBM), rendering them non-responsive to the standard treatment regime of surgery followed by concurrent radiotherapy (RT) and temozolomide. Here, we investigate the efficacy of adding a PARP inhibitor, veliparib, to radiotherapy to treat MGMT unmethylated GBM.

Methods

The inhibition of PARP with veliparib (ABT-888), a potent and orally bioavailable inhibitor in combination with RT was tested on a panel of patient derived cell lines (PDCLs) and patient-derived xenografts (PDX) models generated from GBM patients with MGMT unmethylated tumors.

Results

The combination of veliparib and RT inhibited colony formation in the majority of PDCLs tes

SUBMITTER: Jue TR 

PROVIDER: S-EPMC5356284 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature